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ANCA-associated vasculitis (AAV) is a group of disorders that is caused by inflammation
affecting small blood vessels. Both arteries and veins are affected. AAV includes micro-
scopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA) renamed fromWegener’s
granulomatosis, and eosinophilic granulomatosis with polyangiitis (EGPA), renamed from
Churg–Strauss syndrome. AAV is primarily due to leukocyte migration and resultant dam-
age. Despite decades of research, the mechanisms behind AAV disease etiology are still not
fully understood, although it is clear that genetic and environmental factors are involved.
To improve the understanding of the disease, the genetic component has been exten-
sively studied by candidate association studies and two genome-wide association studies.
The majority of the identified genetic AAV risk factors are common variants. These have
uncovered information that still needs further investigation to clarify its importance. In
this review, we summarize and discuss the results of the genetic studies in AAV. We also
present the novel approaches to identifying the causal variants in complex susceptibility
loci and disease mechanisms. Finally, we discuss the limitations of current methods and
the challenges that we still have to face in order to incorporate genomic and epigenomic
data into clinical practice.
Keywords: ANCA-associated vasculitis, granulomatosis with poliangiitis, microscopic poliangiitis, eosinophilic
granulomatosis with poliangiitis, pharmacogenetics, rituximab, genome-wide association studies
INTRODUCTION
Vasculitis is a group of disorders that is caused by inflammation
affecting blood vessels; it is primarily due to leukocyte migration
and resultant damage (1). It is a multi-system inflammatory-
autoimmune disease that affects both arteries and veins with
consequent tissue damage, especially to the respiratory tract and
kidneys; it causes early mortality, organ failure including end stage
renal disease and chronic morbidity. Children and adults, males
and females, and individuals of any ethnic background can be
affected.
According to the size of the vessel affected, vasculitis can be
classified into large, medium, and small vessels.
Small-vessel vasculitis predominantly involves microscopic
blood vessels with absent or insufficient immune deposits; its asso-
ciation with circulating autoantibodies to neutrophils (ANCA)
has led to these conditions being grouped together as ANCA-
associated vasculitis (AAV) (2, 3).
ANCA-associated vasculitis includes microscopic polyangiitis
(MPA), granulomatosis with polyangiitis (GPA) renamed from
Wegener’s granulomatosis, and eosinophilic granulomatosis with
polyangiitis (EGPA), renamed from Churg–Strauss syndrome (4).
Microscopic polyangiitis is associated with proteinase 3 (PR3)-
ANCA in 26% of cases and with myeloperoxidase (MPO)-ANCA
in 58% of cases (5), while GPA is characterized by PR3-ANCA in
66% of patients and MPO-ANCA in 24% of patients (6).
Interestingly, some patients do not present ANCA; in particular,
in EGPA more than an half are ANCA-negative (7).
ANCA-associated vasculitis has an approximate prevalence of
200 per million and an annual incidence of 20 per million.
The causes of AAV are unknown; it can be considered a com-
plex disease, because multiple genetic factors, combined with
yet unknown environmental factors, are able to influence its
susceptibility (8, 9).
In addition, different phenotypes are influenced by several
triggers and environmental factors (10).
Ethnicity affects the type of AAV, with Chinese and Japan-
ese populations having more MPA and less GPA and EGPA
than Caucasian, and the latter more than the African; geograph-
ical disparities in AAV have been found, with GPA and EGPA
more common in colder climates. In Europe, GPA is more fre-
quent in the north, and the reverse tendency has been found
for MPA (11).
Similar treatment strategies used in trials involving patients
with AAV, considered GPA and MPA as a single disease spectrum
(6), hence the hypothesis that future genetic studies should group
GPA and MPA together (12).
FAMILIAL AAV CASES
The etiology of AAV theoretically involves interaction between
genetics and environmental factors; however, knowledge about
whether AAV clusters in families is poor.
Family recurrence is a strong indicator of a possible heritabil-
ity in multifactorial disorders (13). Furthermore, information on
the possible heritability of AAV is of clinical importance, because
family members often want to know whether AAV increases their
closest relatives at increased risk.
Familial AAV cases have been described but a putative heredi-
tary factor has never been demonstrated.
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The presence of EGPA in a family was described in
two sisters with atopic-type bronchial asthma and negative
perinuclear-ANCA results. The human leukocyte antigen (HLA)
complex and six siblings were investigated, but the authors did not
found a clear pattern of heritability (14).
An interesting study investigated the risk of GPA in relatives
of patients with GPA, because several GPA families have been
described (15). Using Swedish nationwide registers, the authors
compared the occurrence of GPA among 6,670 first-degree rela-
tives and 428 spouses of 1,944 Swedish patients with GPA, with the
occurrence among 68,994 first-degree relatives and 4,812 spouses
of 19,655 control subjects.
Granulomatosis with polyangiitis was present in 2/6,670 first-
degree relatives of patients and in 13/68,994 first-degree relatives
of the controls, with a relative risk of 1.56 (95% confidence interval
0.35–6.90).
The authors concluded that there is no evidence of an increase
in familial risk of GPA, while it was demonstrated in other stud-
ies for other autoimmune disorders, such as inflammatory bowel
disease (IBD), systemic lupus erythematosus (SLE), and multiple
sclerosis (MS).
In several other cases, the familial members were affected by
AAV and another type of vasculitis, underlying the possibility of
common genetic triggers at the basis of vasculitis. In a first case,
polyarteritis nodosa and GPA were observed in several members
of two different families. The authors concluded that genetic fac-
tors are important but not sufficient to express clinical features of
these diseases (16).
In another reported case, a man was affected by EGPA and
his son by GPA (occurred 5 years later). These two patients
lived together in Northern Italy and shared the HLA haplotype
A*03-B*07-C*w07-DRB1*0404-DQB1*0302, a putative marker
of autoimmunity (17). Recently, in an Indoasian family, three
members of the same family with GPA who share the allele HLA-
DPB1*04:01 were described, furthermore demonstrating the HLA
locus is involved in AAV genesis (18).
Pre-GWAS ASSOCIATION STUDIES IN AAV
NON-HLA ASSOCIATIONS
The classical approach for genetic studies applied to AAV is
the case–control strategy, performed investigating candidate-gene
polymorphisms. The dimension of the population, the ethnic-
ity, the number of the investigated polymorphisms and the allele
frequencies mainly determine the power of a study. The non-
HLA single-nucleotide polymorphism (SNP) markers associated
with AAV may contribute to the total variance in susceptibility, in
addition to the HLA genes. The pre-GWAS non-HLA association
studies are listed in Table 1.
Protein tyrosine phosphatase, non-receptor type 22 (lymphoid)
(PTPN22)
The rs2476601 PTPN22 SNP is linked with several autoimmune
diseases. The first associations between rs2476601 SNP of PTPN22
gene and autoimmune diseases were demonstrated with type 1 dia-
betes (T1D) (19) and rheumatoid arthritis (RA) (20); after that,
the finding expanded to other autoimmune diseases, enhancing
the importance of signaling thresholds in disease susceptibility;
even if it is difficult to determine how threshold effects change
disease risk. PTPN22 gene encodes for an intracellular tyrosine
phosphatase that dephosphorylates activating tyrosines, as well as
other molecules involved in TCR signaling. The transgenic mouse
homolog of PTPN22 shows hyperactive T cells (21). In human
beings, the PTPN22 gene can present a SNP at the codon 620
(Arginine to Tryptophan), a change able to destroy the binding
of PTPN22 with the binding partner, the intracellular tyrosine
kinase, Csk. However, the consequence of this for T cell activa-
tion thresholds remains difficult to interpret. The first studies of
PTPN22 risk allele carriers an increased phosphatase activity with
reductions in TCR and BCR signaling (22). Recent studies have
supported the hypothesis that the 620W allele acts as the knock-
out mouse, with loss of function leading to hyper-responsiveness.
The lack of PTPN22 results in changes in T cell populations in
mice, particularly an expansion of T reg cells (23). In addition to T
cell influence, also B cell receptor signaling appears to be affected
by PTPN22 SNP (24). The protein Csk has recently been demon-
strated as a susceptibility gene for several autoimmune diseases
such as Celiac disease (CD) (25), Scleroderma (26) and SLE (27).
Thus, both PTPN22 and Csk may influence disease risk affect-
ing the B cell receptor repertoire development. Taken together,
these data suggest that groups of genes are able to influence recep-
tor signaling thresholds; PTPN22 and Csk, in fact, may influence
the risk of autoimmunity influencing the autoimmune repertoire
selection and the abundance of regulatory cell subsets. (28). It
is highly probable that different mechanisms explain the genetic
associations for every autoimmune disease.
The first study of the rs2476601 SNP in AAV has been per-
formed in a German GPA cohort, demonstrating a statistical
association; interestingly, stratifying the GPA patients in ANCA-
positive and ANCA-negative, the association was stronger in the
ANCA-positive subgroup (29). Later, the result was confirmed in
British GPA and MPA patients (30) and Italian AAV cases (31). The
Italian study confirmed the strong association with the ANCA-
positive subset, while suggested that EGPA is not associated with
the PTPN22 SNP.
Cytotoxic T lymphocyte associated antigen-4
Cytotoxic T lymphocyte associated antigen-4 (CTLA-4) is a reg-
ulatory molecule expressed on T cells that plays a major role in
peripheral tolerance and inhibiting T cell activation (32).
CTLA-4−/− knock-out mice show a phenotype rapidly devel-
oping in lymphoproliferative disease with multiorgan lymphocytic
infiltrations, tissue destruction, splenomegaly, lymphadenopathy,
and elevated serum immunoglobulin with early lethality, demon-
strating a predominant role in suppressing T cell function (33). It is
likely that defective CTLA-4 expression and function are associated
with autoimmune diseases. Furthermore, CTLA-4 activity influ-
ences a negative regulator of both cellular and humoral responses
and mediates antigen-specific apoptosis.
Negative signaling of CTLA-4 has an active role in the reg-
ulation of autoreactive T cells, and disturbance of the normal
control of the CTLA-4 may cause the pathogenesis of autoimmune
diseases.
The CTLA-4 genetic polymorphisms alter activity influencing
the CTLA-4 gene expression.
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Table 1 | Positive genetic association studies in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.
Gene and variation Population Cases Controls OR P -value Other associated
autoimmune diseases
Reference
AAT (Z allele) German 79 GPA 752 3.8a <0.0001 CD (41)
AAT (Z allele) Swedish 88 (66 GPA) No controls 6.0 <0.0001 CD (40)
CD18 (AvaII) German 31 MPO+ 120 2.56 <0.005 / (44)
CD40 (rs4810485) European Descent 895 GPA 1976 0.81 0.002 AT, T1DM, IBD, PS, MS, RA, and SLE (90)
CTLA4 (rs231735) European Descent 895 GPA 1976 0.82 0.001 RA (90)
CTLA (AT)86 repeat European Descent 117 GPA 123 Not available 0.0005 / (40)
CTLA4 (rs3087243) European Descent 895 GPA 1976 0.79 0.000098 GD, RA, T1DM, AITDs, and HA (90)
CTLA4 (rs3087243) British 641 (GPA, MPA, and EGPA) 9,115 1.19 6.4×10−3 GD, RA, T1DM, AITDs, and HT (30)
HLA-DPB1*0401 German 282 GPA 380 2.47 6.4×10−8 / (45)
HLA-DQB1*0303 Japanese 50 MPA 77 2:35 0.017 ACLT, SSc (50)
HLA-DQw7 British 34 GPA, 25 MPA 1,103 2.9 <0.0025 / (47)
HLA-DR3 British 34 GPA, 25 MPA 1,103 0.31 <0.01 / (47)
HLA-DR4 Dutch 241 GPA, 30 MPA, 12 EGPA 9,872 1.7 <0.0001 / (48)
HLA-DR6 Dutch 241 GPA, 30 MPA, 12 EGPA 9,872 0.3 <0.0001 / (48)
HLA-DRB1*04 German 102 EGPA 341 1.86 0.0028 RA, GCA, AD (52)
HLA-DRB1*07 Italian 48 EGPA 350 2:42 0.0042 SLE, AD (51)
HLA-DRB1*07 German 102 EGPA 341 1.57 0.046 SLE, AD (52)
HLA-DRB1*09 European Descent 76 GPA 4,039 4.00a 0.005 / (49)
HLA-DRB1*0901-DQB1*0303 Japanese 50 MPA 77 2:44 0.0037 GD, MG, T1DM, RA, and SLE (50)
HLA-DRB1*13 German 102 EGPA 341 0.50 0.019 Early childhood, MG (52)
HLA-DRB3 Italian 48 EGPA 350 0:54 0.028 childhood ALL (51)
HLA-DRB3 German 102 EGPA 341 0.61 0.004 childhood ALL (52)
HLA-DRB4 Italian 48 EGPA 350 2:49 0.00023 HT (51)
HLA-DRB4 German 102 EGPA 341 1.87 0.0002 HT (52)
IL-10 Swedish 32 GPA 109 / <0.05 SLE, SSc, KD, PM, DM, PV, UC, SS,
GD, MG, PS, and ALPS.
(39)
IL-10 haplotype German 103 EGPA 507 2:16 0.0003 SLE, SSc, KD, PM, DM, PV, UC, SS,
GD, MG, PS, and ALPS.
(38)
(Continued)
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Table 1 | Continued
Gene and variation Population Cases Controls OR P -value Other associated
autoimmune diseases
Reference
IL2RA rs41295061 British 675 (GPA, MPA and EGPA) 8,936 0.77 0.012 T1DM, SLE (30)
PRTN3 -564G German 66 GPA 106 0.5 <0.01 / (44)
PTPN22 (rs2476601) European Descent 895 GPA 1976 1.35 0.002 CD, PS, RA, SLE, T1DM, GD, HT,
and some forms of JA
(90)
PTPN22 (rs2476601) German 199 GPA 399 1.8 0.002 CD, PS, RA, SLE, T1DM, GD, HT,
and some forms of JA
(46)
PTPN22 (rs2476601) Italian 143 GPA, 102 MPA, and 99
EGPA
945 1.91 GPA; 2.31
GPA ANCA+
0.005 GPA; 0.00012
GPA ANCA+
CD, PS, RA, SLE, T1DM, GD, HT,
and some forms of JA
(31)
PTPN22 (rs2476601) British 641 (GPA, MPA and EGPA) 9,115 1.4 1.4×10−4 CD, PS, RA, SLE, T1DM, GD, HT,
and some forms of JA
(30)
TLR9 3-SNP haplotype German, Dutch, British 646 GPA, 164 EGPA, and 53
MPA German AAV; 273 GPA,
53 EGPA and 100 MPA Dutch
and British AAV cases
1898 1.64 0.000044 IBD (37)
FCGR3B CNVs number high British 556 (GPA, MPA and EGPA) 286 / 1×10−8 RA (57)
FCGR3B CNVs number low British 80 GPA 190 / 0.003 SLE (69)
FCGR3B CNVs number low British 76 MPA 190 / 0.0003 SLE (69)
FCGR3B CNVs number low French 84 GPA 181 / 0.0001 SLE (69)
DEFB4 CNVs number high Chinese 112 AAV (ANCA+ and biopsy
proven necrotizing
glomerulonephritis)
523 / 0.009 SLE, PS, COPD, IBD, HIV
infection, and SAP
(65)
ANCA, autoantibodies to neutrophils; OR, odds-ratio; CNVs, copy number variations; GPA, granulomatosis with poliangiitis; MPA, microscopic poliangiitis; EGPA, eosinophilic granulomatosis with poliangiitis; CD,
Crohn’s disease; T1DM, diabetes mellitus type1; CD, celiac disease; RA, rheumatoid arthritis; MS, multiple sclerosis; pSS, primary sicca syndrome; AT, autoimmune thyroiditis; IBD, inflammatory bowel disease;
AITD, autoimmune thyroid disease; GB, Guillain–Barrè syndrome; MG, myasthenia gravis; ACLT, autoimmune chronic lymphocytic thyroiditis; SSc, systemic sclerosis; GCA, giant cell arteritis; ACPAs, anti-citrullinated
protein antibodies; KD, Kawasaki disease; DM, dermatomyositis; PV, pemphigus vulgaris; UC, ulcerative colitis; SS, Sjogren’s syndrome; ALPS, autoimmune lymphoproliferative syndrome; SAP, severe acute
pancreatitis; GD, Grave’s disease; COPD, chronic obstructive pulmonary disease; PS, psoriasis; HT, Hashimoto thyroiditis; JA, juvenile arthritis; AD, atopy.
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An AAV associated polymorphism is the allele (named allele
86) of the CTLA-4 microsatellite polymorphism (AT)n, which
maps in the 3′-untranslated region (3′-UTR) of exon 3. Individ-
uals with long CTLA-4 (AT)n repeat alleles show hyper-reactive
T cells.
The CTLA-4 (AT)n 86 allele has been demonstrated to be
important for maintenance of normal levels of CTLA-4 expres-
sion and seems to balance T cell activation/inhibition. A study
in European descent GPA patients (34) confirmed findings from
a Scandinavian cohort in which a positive association with the
long alleles of (AT)n in the CTLA-4 3′-UTR was demonstrated.
Evidences of a blockade of T cell costimulation using CTLA-4Ig
seems to be a potential therapeutic intervention, alternative to
standard treatment with immunosuppressive agents. In a recent
open-label trial of 20 patients with non-severe relapsing GPA, the
safety and efficacy of abatacept were investigated. The authors
concluded abatacept was well tolerated and an high frequency of
disease remission and prednisone discontinuation were observed.
This study demonstrated anti-CTLA4 may be an option in the
treatment of some subgroups of AAV (35).
A second polymorphism in CTLA-4 gene investigated in AAV
is the SNP rs3087243. A large British study found the minor allele
(A) of this SNP is protective for AAV (30).
Toll-like receptors
Evidences are emerging about the role of Toll-like receptors (TLRs)
in the development of the autoimmune diseases (36).
Toll-like receptors are a family of innate receptors whose speci-
ficities are predetermined in the germline. Therefore, TLRs have
evolved to recognize conserved features of microbes. Viruses typ-
ically lack the conserved features common to other pathogen
classes, so the innate immune system has evolved to recognize
viral nucleic acid as a hallmark of viral infection.
TLR9 signaling may be involved in disease pathology, favor-
ing models of infectious agents triggering AAV development.
Unmethylated CpG motifs within bacterial nucleic acid were the
first ligands identified to activate TLR9. Since then, many DNA
viruses have also been shown to activate this TLR, including those
from the herpesvirus and adenovirus. Bothα- andβ-herpes viruses
have genomes that are rich in CpG motifs. The contribution
of TLR9 recognition of these viruses has clearly been reported
in vitro (37).
In order to investigate the genetic contribution of TLR9 on
the susceptibility and clinical manifestation of AAV, four SNPs
in TLR9 have been genotyped in 863 German AAV cases and
1344 healthy controls (38). In the replication step, significant
results were investigated in a cohort of 426 Dutch and British
AAV cases. Interestingly, in GPA patients the association with
genotypes and haplotypes was predisposing (OR >1), while in
MPA was protective (OR <1). When cases were stratified accord-
ing to ANCA status rather than to clinical entity, the association
was confirmed; in fact, the results showed a strong overall differ-
ence in TLR9 allele/haplotype frequencies between PR3-ANCA
and MPO-ANCA cases. These results confirmed the findings
of the EVGC GWAS about the genetically differences between
PR3-ANCA and MPO-ANCA AAV.
Interleukin-10
Interleukin-10 (IL-10), which was originally named cytokine syn-
thesis inhibitory factor, is a cytokine that is produced by type T-
helper cells. IL-10 presents anti-inflammatory properties, with the
inhibition of immune mediator secretion, antigen presentation,
and phagocytosis.
A study investigated the presence of IL10 gene polymorphisms
in EGPA and GPA patients of European ancestry (39). Three SNPs
in the IL10 gene promoter (IL10-3575, IL10-1082, and IL10-592)
were analyzed in 403 GPA patients and 103 EGPA patients, com-
pared with 507 German controls. The IL10-3575/-1082/-592 TAC
haplotype, part of the extended ancient haplotype IL10.2, was
highly significantly associated with ANCA-negative EGPA, provid-
ing further evidences that AAVs have distinct genetic backgrounds.
Other studies of the IL-10 SNPs were performed both in German
and Swedish population, suggesting the IL-10 may influence the
production of autoantibodies (40).
SERPINA1
The SERPINA1 gene encodes for α1-antitrypsin, a neutral serine
protease inhibitor, which includes proteinase 3; this is the major
inhibitor of PR3 activity, and is supposed to limit the damage to
the local tissues. This mechanism may be crucial in AAV, because
the decreased function of α1-antitrypsin potentially results in per-
sistence of PR3 in inflammatory tissue, with the final consequence
of ANCA generation.
The SERPINA1 gene is highly polymorphic; the Z allele
(Glu342Lys) in α1-antitrypsin (AAT) deficiency is a combined
deficiency and dysfunctional allele.
Several studies investigated the role of the Z allele in AAV,
showing that heterozygous patients for the Z variant of the SER-
PINA1 gene have an increased risk than the general population of
developing GPA (41, 42).
PRTN3
PRTN3 gene encodes for proteinase 3 (PR3) protein, a neutrophil
intracellular protease that is the main antigen of ANCA autoan-
tibodies; it is located on the plasma membrane of a subset of
neutrophils. The rate of this membrane PR3-positive neutrophils
subset is characteristic of an individual, and this semms to be
genetically determined (43).
In GPA patients, there is an increased number of PR3-positive
neutrophils and an elevated level of PRTN3 expression compared
with controls. Increased levels of PRTN3 expression are associated
with an elevated risk of relapse and with an increased relapse rate;
this supports the idea that PR3 expression on the membrane of
neutrophils plays a role in the pathophysiology of PR3-AAV (44).
The promoter and coding regions of the PRTN3 gene were
sequenced searching for genetic variants in 79 GPA patients
and 129 healthy controls. Seven SNPs, one amino acid change
(Val119Ile), one 84 bp insertion/deletion, and a microsatellite were
found. An association with GPA was demonstrated for the A-564G
polymorphism in the PRTN3 promoter; this variation affects a
candidate transcription factor-binding site. The authors suggested
the overexpression of PRTN3, might predispose the patient to the
development of AAV (45).
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HLA ASSOCIATIONS
The HLA region, located on chromosome 6p21 and extended for
7.6 Mb, is the most dense gene region within the human genome
encoding more than 250 expressed loci including several key
immune response genes. The region can be subdivided in class
I, II, and III regions and contains the highest number of polymor-
phisms and the most dense linkage disequilibrium in the human
genome. In the last 50 years, numerous associations between the
HLA region and autoimmune disease have been demonstrated.
The association between HLA and AAV has been largely inves-
tigated, for different populations and with several methods. The
pre-GWAS HLA association studies are listed in Table 1.
The most studied AAV has been GPA, with demonstrated asso-
ciation for DPB1*0401 (46, 47), DQw7 (48), and different DRB1
genes, some with protective effects [DRB1*03 (47), DRB1*06
(48)], other with causative effects [DRB1*04 (49), DRB1*09 (50)];
in some cases the populations were small and the results have not
been replicated.
Microscopic polyangiitis has been investigated in few studies,
mainly because the incidence of the disease is smaller than GPA.
Associations were demonstrated with DRB1*03 (48) and DRB1*06
(49) (protective effects), while DRB1*04 (49) and the haplotype
DRB1*0901-DQB1*0303 (51) have causative effects.
Finally, EGPA has been mainly investigated in Italian (52)
and German (53) populations, with the same results. The HLA
genes DRB4 and DRB1*07 have causative effects while DRB3 and
DRB1*13 with protective effects. Furthermore, the first study strat-
ified EGPA in the two major clinical subsets (54), ANCA-negative,
with organ damage mainly mediated by tissue eosinophilic infil-
tration and ANCA-positive, with features of small-vessel vasculitis;
analyzing the HLA-DRB4 in patients categorized by different num-
bers of vasculitic manifestations (purpura, alveolar hemorrhage,
mononeuritis multiplex, rapidly progressive glomerulonephritis,
and constitutional symptoms) suggested that the gene frequency
correlates with the different number of vasculitis symptoms.
All the studies examined relative small population, and need
to be confirmed in large studies with focused GWAS. Further-
more, the different associations between GPA, MPA, and EGPA
demonstrate the three AAV have a different genetic background.
GWAS AAV GENETICS
The main aim of a GWAS is to identify common genetic vari-
ation associated with well phenotyped disease in a non-biased
method. Inherent to the properties of association-based statistics,
the premise for conducting GWAS is based on the assumption that
disease risk is associated with relatively common variants with a
minor allele frequency greater than 2–5%. The goal is to identify
frequency differences in polymorphisms between cases and con-
trols. As a result, the study analyses a large sample size with a strong
statistical correction in order to avoid spurious associations due
to false-positive findings. The occurrence of linkage disequilib-
rium is used because not all the polymorphisms can be genotyped
to detect an association. The larger the population studied for a
disease, the more associated variants can be discovered (55).
To date, two different GWASs have been performed in AAV. The
first one was performed by the European Vasculitis Genetic Con-
sortium (EVGC) (56) and the second one by the VCRC (Vasculitis
Clinical Research Center) (57). The two GWASs differed for the
study design.
In 2012, the EVGC performed the first GWAS of AAV (ANCA-
positive GPA and MPA) in order to identify common or specific
genetic-risk factors.
The clinical diagnosis of AAV was evaluated according to the
European Medicines Agency algorithm, supported by either a
positive ANCA assay or a diagnostic biopsy.
The EVGC GWAS was performed in 1233 UK patients with
AAV and 5884 controls (from the Wellcome Trust Case–Control
Consortium) and was replicated in 1454 Northern European case
patients and 1666 controls. A total of 2687 AAV patients of Euro-
pean ancestry and 7650 controls were analyzed. The main results
of the EVGC GWAS are listed in Table 2.
In order to confirm the GWAS data, 156 SNPs were genotyped
in a replication cohort of 1454 AAV patients and 1666 controls.
In addition to the SNPs genotyped in the chip, three additional
SNPs were included: the proteinase 3 gene (PRTN3), which is a
major ANCA autoantigen, the interleukin-2-receptor alpha gene
(IL2RA) and the protein tyrosine phosphatase, non-receptor type
22 gene (PTPN22) because were found to be associated with AAV
in previous studies.
Combined analysis of the discovery and replication cohorts
showed that these SNPs were statistically significant. Three of them
mapped in the HLA locus, with the most significant, which maps
in the HLA-DPB1 gene, while a fourth associated SNP maps in
the SERPINA1 locus at 14q32; this demonstrates that the suscep-
tibility loci are located bot on HLA and in non-HLA regions. The
SERPINA1 gene encodes for the protein α1-antitrypsin, a neutral
serine protease inhibitor, which includes proteinase 3. Associations
with the rare Z (null) allele of SERPINA1 have been described in
previous studies, but the significance were low (58).
The SNP in the SERPINA1 locus is in linkage disequilibrium
with the Z allele, suggesting that the causal variant at the SER-
PINA locus is either the Z allele of SERPINA1 or is in close linkage
disequilibrium with it.
In order to investigate whether GPA and MPA are genetically
distinct clinical diseases, a further statistical analysis of the dis-
covery cohort was subdivided in the two diseases according with
clinical data comparing the seven most significant SNP associated
with AAV in the two diseases. Interestingly, the three HLA and
SERPINA1 SNPs differed significantly between GPA and MPA,
with almost all the association related to GPA.
Finally, a comparison between the subgroups of patients with
PR3-ANCA and with MPO-ANCA, evidenced significant differ-
ences at the HLA, SERPINA1, and PRTN3 loci, demonstrating a
genetic association with PR3-ANCA but not with MPO-ANCA.
In the GPA subgroup, the associations were found only in PR3-
ANCA patients, not in MPO-ANCA patients. Within the MPA
group, the findings were the same: an association of PR3-ANCA
and the HLA-DP and SERPINA1 SNPs. The most significant SNP
associated with AAV in non-MHC regions was the rs7151526, both
in GPA and PR3-ANCA subgroups; the Z allele of this SNP maps
in the SERPINA1–SERPINA11 locus at 14q32.
The major finding of the EVGC GWAS was that the strongest
association of all these genetic polymorphisms appeared to be
related with ANCA specificity rather than the clinically defined
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Table 2 | Associations of single-nucleotide polymorphisms (SNPs) and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (GPA+
MPA), According to Cohort.
Combined cohort
(N =2267 case patients,
6858 controls)
Gene Chromosome SNP (Minor Allele) Nucleotide change OR P -value
SNPs WITH GENOME-WIDE SIGNIFICANCE IN COMBINED COHORT
HLA-DP 6 rs3117242 A>G 3.67 1.5×10−71
HLA-DQ 6 rs5000634 A>G 0.80 2.9×10−9
COL11A2 6 rs3130233 A>G 1.51 7.8×10−15
COL11A2 6 rs3117016 A>G 1.83 6.4×10−24
SERPINA1 14 rs7151526 A>C 0.59 2.4×10−9
Clinical syndrome
GPA vs. control
(N =1683 vs. 6858)
MPA vs. control
(N =489 vs. 6858)
Gene Chromosome SNP Nucleotide change OR P -value
ASSOCIATIONS OF SNPs AND ANCA – ASSOCIATED VASCULITIS, ACCORDINGTO CLINICAL AND ANCA SUBGROUPS
HLA-DP 6 rs3117242 A>G 5.39 3.1×10−85
HLA-DQ 6 rs5000634 A>G 0.83 2.2×10−6
ARHGAP18 6 rs1705767 A>C 0.78 3.3×10−7
SERPINA1 14 rs7151526 A>C 0.54 4.4×10−10
PRTN3 19 rs62132295 A>G 0.78 2.6×10−5
MOSPD2 X rs6628825 A>G 0.80 2.6×10−6
ANCA specificity
Proteinase 3 vs. control
(N =1521 vs. 6858)
Myeloperoxidase vs. control
(N =556 vs. 6858)
Gene Chromosome SNP Nucleotide change OR P -value OR P -value
HLA-DP 6 rs3117242 A>G 7.03 6.2×10−89 1.55 3.2×10−2
HLA-DQ 6 rs5000634 A>G 0.86 3.3×10−5 0.65 2.1×10−8
ARHGAP18 6 rs1705767 A>C 0.73 5.2×10−8 0.87 1.0×10−2
SERPINA1 14 rs7151526 A>C 0.53 5.6×10−12 0.84 2.8×10−1
PRTN3 19 rs62132295 A>G 0.73 2.6×10−7 1.10 2.2×10−1
MOSPD2 X rs6628825 A>G 0.77 6.1×10−7 0.86 6.3×10−1
GPA, granulomatosis with poliangiitis, MPA, microscopic poliangiitis, EGPA, eosinophilic granulomatosis with poliangiitis.
syndromes. The genetic background with autoantibody specificity
evidenced in this study could impact the clinical classifications of
GPA and MPA and therapeutic options (59).
Further GWAS with large ANCA-negative AAV are needed in
order to find the genetic basis of ANCA-negative GPA and MPA.
A second GWAS was performed by the VCRC in 492 GPA
patients (white subject of European descent) and 1,506 healthy
controls; the data were replicated in a second cohort of 528
GPA patients and 1,228 controls. The main results of the VCRC
GWAS are listed in Table 3. Association analysis of the two com-
bined cohort (750 patients and 1,820 controls) showed that the
strongest association mapped in the HLA region, with the SNP
rs9277554 (HLA-DPB1 gene, P = 1.92× 10−50), and rs9277341
(HLA-DPA1 gene, P = 2.18× 10−39). An independent single SNP,
rs26595, showed also association with GPA in the combined cohort
(P = 2.09× 10−8). This SNP maps on chromosome 5 in prox-
imity of the SEMA6A gene, which encodes for a protein called
semaphorin 6A. Semaphorins are involved in many physiologic
processes, such as vasculogenesis, cardiogenesis, osteoclastogene-
sis, tumor metastasis, and immune regulation (60, 61). The role
of SEMA6A in GPA is still unclear; a possible theory explains that
semaphorins have an important role in the immune response in
autoimmune and allergic disorders (62). The association between
the rs26595 SNP of the SEM6A6 gene and GPA was recently inves-
tigated in 879 GPA patients, 150 MPA patients and 191 EGPA
patients, compared with 1,376 healthy control subjects (63). All
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Table 3 | Results of genome-wide association (stage 1) and replication (stage 2a) analyses of GPA association.
Combined analysis (n=750 case patients,
n=1820 controls)
Gene Chromosome SNP Nucleotide change OR P -value
HLA-DPB1 6 rs9277554 T>C 0.24 1.92×10−50
HLA-DPA1 6 rs9277341 C>T 0.33 2.18×10−39
Non-HLA region
WSCD1 17 rs7503953 A>C 1.50 1.93×10−7
COBL 7 rs1949829 T>C 1.78 4.19×10−7
CCDC86 11 rs595018 A>G 1.46 1.60×10−7
DCTD 4 rs4862110 C>T 1.44 2.14×10−6
Combined analysis (n=987 case patients,
n=2731 controls)
SEMA6A 5 rs26595 C>T 0.74 2.09×10−8
c-ANCA-positive patients vs. controls
(patients, n=578; controls, n=1,820)
Gene Chromosome SNP Nucleotide change OR P -value
VCRC GWAS: associations of MHC Loci with c-ANCA-positive GPA
HLA-DPB1 6 rs9277554 T>C 0.16 4.7×10−57
HLA-DPA1 6 rs9277341 C>T 0.27 2.30×10−42
GPA, granulomatosis with poliangiitis; SNP, single-nucleotide polymorphism; OR, odds-ratio; VCRC, Vasculitis Clinical Research Consortium; ANCA, autoantibodies to
neutrophils.
of the subjects were white Europeans. ANCA status was avail-
able for 90% of the patients. The authors did not observe any
statistically significantly different allele frequencies between AAV
patients and controls, not confirming the findings from the initial
VCRC GWAS. Between the two studies the approaches of analysis
is different, raising the need for further genetic association studies
in GPA.
SERPINA1 has been the only non-MHC locus associated
with AAV. However, the SNP strongly associated in that study
(rs7151526) is located 557 bp from rs1956707 and was not inde-
pendently associated in that population; the reason may be the two
SNPs are not in linkage disequilibrium.
The potential HLA associations to specific GPA subsets were
also investigated. Comparisons of the HLA risk allele frequencies
between the PR3-cANCA positive subgroup (88% of cases) and the
ANCA-negative subgroup showed that the associations with HLA–
DPB1 (rs9277554, P = 4.7× 10−57) and HLA–DPA1 (rs9277341,
P = 2.30× 10−42) were caused by the PR3-cANCA positive group,
a finding, which confirms previous data suggesting genetic differ-
ences between ANCA-positive and ANCA-negative GPA.
The differences between the two GWAS results may be
explained to different factors, such as phenotypes in the patient
cohorts (i.e., ANCA-positive GPA and MPA in the EVGC versus
ANCA-positive and -negative GPA in VCRC) and in the genetic
and statistical approaches.
Further genetic studies of additional cohorts are needed to clar-
ify the AAV genetic background. The two different GWAS have
identified SERPINA1, SEMA6A, and HLA loci as significant factors
related to AAV risk and demonstrate that the strongest association
is linked to HLA–DPB1*04. Although the results must be con-
firmed in further studies, they highlight that MPA and GPA might
be considered two distinct clinical entities, and that ANCA speci-
ficity might be segregated in different subgroups, probably better
than the distinction actually made between GPA and MPA; as
well, the autoantigen PR3 might be a direct player/trigger in the
pathophysiology of GPA.
COPY NUMBER VARIATIONS
Copy number variations (CNVs) have been defined by the
presence of variable copies (deleted or duplicated) of genomic
regions of 1 kb or more in different individuals; CNVs repre-
sent an important source of genetic variation in the human
genome (64).
Approximately 360 Mb pairs (12% of the human genome is
represented by CNVs), with a preponderance of smaller size
rearrangements (<20 kb). The genomic regions with these CNVs
contain hundreds of genes and other functional elements, and
many CNVs have a population frequency higher than 1% [copy
number polymorphisms (65)].
CNVs can change the gene dosage of particular gene, influenc-
ing the susceptibility to a specific disease.
Immunological genes are frequently involved in CNVs, perhaps
because this represents a mechanism to expand the recognition
repertoire. To date, a low number of studies have been performed
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in autoimmune diseases, even if immunological genes have the
potential to be affected by CNVs.
A first demonstration that CNVs are linked with AAV has been
found in a Chinese population; in a study of 112 AAV (ANCA
positive and biopsy proven necrotizing glomerulonephritis)
patients and 523 controls, an association of CNVs in the DEFB4
gene has been statistically demonstrated (65). This gene belongs
to the β-defensin family genes, underlying a possible mecha-
nism of susceptibility in some inflammatory disorders, such as
psoriasis (Ps), chronic obstructive pulmonary disease, IBD, HIV
infection, and severe acute pancreatitis. Furthermore, at mRNA
level, there is a correlation between CNVs and β-defensin gene
expression (66).
Defensins show a vast spectrum of anti-microbial activity, rep-
resenting an important factor in the first defense against micro-
organisms and connect the innate and adaptive immune system.
These functions are performed with the production of chemotactic
factors inducing pro-inflammatory cytokines.
A further CNV analysis in AAV has been performed studying
the FCGR3B gene.
Low-affinity Fc-receptors (FcgR) play a crucial role in the initi-
ation and regulation of the antibody-mediated immune response,
linking humoral, and cellular immunity. These receptors are able
to recognize the constant domain of IgG and are involved in
the mobilization of macrophages, natural killer T-cells, and neu-
trophils to regions of immune complex deposition. FCGRs also
play an important role in the recognition and clearance of immune
complexes, and as modulators of B-cell activity. In particular,
FCGR3B CNV has been investigated in risk of autoimmunity (67).
Association between FCGR3B CNV and a number of autoim-
mune disorders has been reported in European populations,
including SLE (68), RA (69), and in Japanese population for
ulcerative colitis (64).
In the investigation of the association between FCGR3B CNV
and AAV, it is noteworthy that the approach they used for sta-
tistical analysis; in a previous paper, an association with AAV
and low FCGR3B CNV by Quantitative Polymerase Chain Reac-
tion was utilized (70), but analyzing a UK Caucasian vasculitis
cohort with a triple paralog ratio test the association was not
confirmed, suggesting that the initial finding may have been a
false-positive resulting deriving from the lack of robustness in the
qPCR assay (71).
EPIGENETICS
Epigenetics can be defined as those mechanisms that cause sta-
ble changes of gene expression without influencing the primary
nucleotide sequence; it might explain why human body cells have
highly specific phenotypes, even though they all carry an identical
genome (72).
Epigenetic mechanisms are particularly important for autoim-
munity, since the expression of pro-inflammatory genes (like
TNF-α) is regulated at the chromatin level.
Little is known about epigenetics in AAV; in 2010 a study inves-
tigated the role of epigenetics in AAV (73), this was based on the
concept that the development of AAV basically needs two things: a
dysregulation in immune response able to produce autoantibod-
ies directed to PR3 and MPO and high expression of these major
ANCA autoantigens in mature neutrophils. When the autoanti-
bodies find the aberrantly autoantigens presented on neutrophils
they can stimulate activation of neutrophils causing vascular
inflammation. The data suggested that epigenetic modifications
(mainly DNA methylation and histone modification) associated
with gene silencing are able to influence ANCA autoantigen encod-
ing genes, potentially influencing the expression of PR3 and MPO
in AAV patients, and suggesting that epigenetic events may be
important in the development of autoimmunity.
This study and other investigations in autoimmune diseases
suggest epigenetics globally affects these disorders and that the
persistence of the epigenomic changes could lead to an aberrant
gene expression, contributing to the perpetuation of the disease
mechanisms.
PHARMACOGENETICS
The pharmacogenetics is the study of the role of inherited and
acquired genetic variation in drug response (74). These type of
studies scans for candidate genetic variants of subjects based on
the different type of response for a specific drug, in a case–controls
design. Pharmacogenetics has the potential to predict response
and/or toxicity based on genetic background and has the poten-
tial to personalize therapy. The aim of the pharmacogenetics is to
personalize the specific theraphy, enhancing the response and min-
imizing the side effects of the chemotherapeutic drugs. In recent
years, the development of monoclonal antibodies directed against
a particular immunological protein has permitted the treatment
of several autoimmune disorders [i.e., RA and AAV, autoimmune
hemolytic anemia, T1D, Sjogren’s syndrome (Sj)]. One of these
most used drugs is rituximab (RTX), a chimeric monoclonal anti-
body directed against the protein CD20. RTX is able to destroy
normal and malignant B cells that present CD20 (primarily found
on the surface of the B cells) on their surfaces; this is useful for
the treatment of those diseases characterized by a high number of
iperactive or dysfunctional B cells.
Unfortunately, RTX has several side effects, such as disabil-
ity, cardiac arrest, syndrome of tumor lysis (which can cause
acute renal failure), infections (Hepatitis B reactivation), pro-
gressive multifocal leukoencephalopathy, immune toxicity (with
depletion of B cells), and pulmonary toxicity. Sometimes RTX
can cause death. RTX acts with a mechanism mediated by the Fc
portion, including apoptosis of CD20-positive cells, complement-
dependent cytotoxicity (CDC), Fcg receptor (FcgR)-mediated
mechanisms, antibody-dependent cellular cytotoxicity (ADCC),
and phagocytosis. These combined effects can stimulate elimina-
tion of B cells with the generation of normal B cells developed
from lymphoid stem cells (75).
Several polymorphisms able to influence the RTX activity have
been identified. FCGR3A gene, which encodes the FcgRIIIa pro-
tein, presents the c.559 SNP, which can change the aminoacid in
position p.158 of the FcgRIIIa, affecting the affinity for human
IgG1 (76, 77); as a consequence, human IgG1 binds more strongly
the NK cells homozygous for FCGR3A-158V than to NK cells
homozygous for FCGR3A-158F.
Because FcgRIIIa is expressed only by monocytes/macrophages
and NK cells (the main actors in ADCC), it has been postulated
that patients homozygous for FCGR3A-158V show significantly
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better responses to RTX because they have enhanced ADCC activ-
ity compared with FCGR3A-158F carriers. This was confirmed in
other studies using RTX (78, 79).
Weng and Levy (78) also showed that the FCGR2A-131H/R
polymorphism significantly affects response and time to pro-
gression after RTX treatment, with better results for FCGR2A-
131H homozygous patients. These results were not confirmed in
other studies, that found no impact on response (80), suggesting
the association may arise from linkage disequilibrium between
FCGR3A/FCGR2A polymorphisms (81, 82).
In addition to the influence of FCGR2A and FCGR3A in
RTX action, it is important to consider that the drug binds to
aminoacids 170–173 and 182–185 on CD20 protein; these residues
are physically close to each other for the creation of a disulfide bond
between amino acids 167/183, creating a potential mechanism of
different response to RTX based on CD20 mutations.
To date, there is no evidence that inherited mutations or
polymorphisms of the CD20 gene (called MS4A1) influence the
response to RTX (83).
Recently, an Italian group selected 132 patients with systemic
autoimmune diseases treated with RTX.
Of these patients, 81 (61.4%) were SLE patients, 16 (12.1%)
presented different inflammatory myopathies such as polymyosi-
tis and dermatomyositis, 13 (9.8%) were AAV patients (GPA,
EGPA and MPA); the remaining 22 patients suffered of other sys-
temic autoimmune diseases such as Sj, systemic sclerosis (SSc), or
autoimmune hemolytic anemia.
Genotyping for FCGR3A-158F/V (rs396991) gene polymor-
phism was performed, in order to determine whether the SNP
158F/V in the FCGR3A gene, influences the RTX response in
systemic autoimmune disease patients.
The type of drug response after RTX infusion was evaluated:
61% of the patients had a complete response, partial response 27
and 12% did not respond to the treatment. A statistically signif-
icant difference was observed in 158 V allele frequency between
responder (38%) and non-responder (16%) patients (P = 0.01;
OR= 3.24). RTX was also more effective in the 158 V allele car-
riers (94%) than in homozygous 158FF patients (81%): P = 0.02;
OR= 3.96. This study shows that FCGR3A-158F/V SNP influ-
ences the response to RTX in autoimmune diseases, including AAV
(results need to be replicated in a larger population, because the
AAV population was small) (84).
Another drug used in the treatment of AAV is the cyclophos-
phamide (CP), a bifunctional DNA alkylating agent; this drug
is used for the treatment of pediatric and adult malignancies,
because it is characterized by anti-tumor activity in human beings
(85). At low dosage, CP is a potent immunomodulatory used as
second-line therapy (86). Like other chemotherapy, CP shows dif-
ference in efficacy and toxicity in patients. CP side effects include
cardiotoxicity, nephrotoxicity, neurotoxicity, infertility, bladder
toxicity, myelosuppression, and leukemogenesis. CP bioactivation
and/or detoxification has demonstrated to be influenced by dif-
ferent SNPs; with the era of –omics, however, new methods can
increase knowledge about the genetic background able to influence
CP activity (87). Finally, genes found having pharmacokinetic and
pharmacodynamic effects, require replication in larger and more
diverse patient populations.
OVERLAP WITH OTHER AUTOIMMUNE DISEASES
Several HLA and non-HLA susceptibility variants appear to
increase risk in autoimmune diseases, which share the same path-
way even if the diseases are different. In recent years, candidate-
gene studies in AAV have often investigated variants previously
associated to other autoimmunity diseases.
The two most investigated genes, which are potentially associ-
ated with autoimmune diseases are CTLA-4 and PTPN22.
The CTLA-4 SNPs rs3087243 and rs231735 have been previ-
ously found to be associated with RA and T1D, and replicated in
GPA (34, 88–90).
In 2012, a study examined the association between previously
identified autoimmune disease susceptibility loci and GPA, try-
ing to demonstrate shared genetic susceptibility variants (91).
The study examined 431 GPA patients and 473 controls, all of
European ancestry. Multiple SNPs were assessed to be associ-
ated with GPA, shared with other autoimmune diseases such as
Crohn’s disease, T1D, SLE, RA, CD, and ulcerative colitis. SNPs in
CTLA-4 gene were significantly associated with GPA in the single-
marker meta-analysis [odds ratio (OR)= 0.79, P = 9.8× 10−5].
The genetic-risk score for RA susceptibility markers was signif-
icantly associated with GPA (P = 5.1× 10−5). The results may
demonstrate that RA and GPA share a similar genetic background.
This study supports the findings of a previous epidemiologic
study, which showed an increased frequency of RA among off-
spring of GPA patients (92). GPA and RA present several dif-
ferences, such as the pulmonary and renal manifestations (not
commonly observed in RA, but frequent in GPA); furthermore,
inflammatory arthritis (characteristic of RA), is not present in
every patients with GPA.
Interestingly, this meta-analysis showed that other loci differ-
ent from CTLA-4 previously found to be associated with common
autoimmune diseases were not statistically significantly associated
with GPA in this study.
The PTPN22 rs2476601 (R620W) polymorphism has been
found to be associated with GPA (29) and with multiple other
autoimmune diseases (23).
Recently, a comprehensive meta-analysis (93) showed that
PTPN22 C1858T SNP is strongly associated with nine autoim-
mune diseases: T1D, RA, SLE, Graves’ disease, Addison’s disease,
AAV, juvenile idiopathic arthritis, myasthenia gravis and Graves’
disease with other concomitant autoimmune diseases, with the T
allele increasing the risk of disease. The association suggests that
is possible the presence of a common mechanism shared by these
autoimmune diseases. Further investigation of these mechanisms
may in the future shed light in the pathogenesis of the autoim-
mune diseases. The studies related to the PTPN22 R620W variant
suggest that there is a correlation between the presence of autoan-
tibodies and the development of self-reacting antibodies, with the
PTPN22 620W, which may affect autoimmune response on several
levels, including generation and activation of autoimmune cells.
Based on this theory, the PTPN22 function in autoimmune dis-
ease manifestations seems to affect generation and activation of
immune cells (93).
In conclusion, the sharing of a similar genetic background
suggests that different autoimmune diseases may have similar
pathogenic mechanisms, and the shared association with CTLA-4
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and PTPN22 variants affects the threshold for activation or
deactivation of autoreactive T cells.
Further GWAS results and other genomic approaches can
increase the knowledge of the genetic background of AAV, search-
ing for rare variants that would be not investigated in previous
studies.
FUTURE PERSPECTIVES
In complex diseases, it is necessary to search new associated loci,
but also replicate already known susceptibility variants. Novel
demonstrated loci confer low increases in susceptibility to the dis-
ease, but they may evidence new pathways important in etiology
or that may be crucial for pharmacogenetic applications. To date,
the HLA complex still show the strongest association for several
autoimmunity diseases (like AAV), but different non-HLA genes
associated with autoimmunity are now under investigation.
There are now several methods available for investigating more
deeply the genomic regions associated with autoimmunity.
IMMUNOCHIP
In recents years, Illumina produced ImmunoChip genotyping
SNPs microarray, which allows immunogenetics studies of the
major inflammatory and autoimmune diseases, mapping with
high-density previous established GWAS significant loci. The
Immunochip contains 196,524 polymorphisms, with 195,806
SNPs and 718 small insertion/deletions, enabling cheap fine map-
ping of loci for common and rare variants. Being immunogenet-
ics highly involved in inflammatory and autoimmune disorders,
Immunochip includes a dense coverage of the HLA Complex
SNPs; this enables deep replication and imputation of the major
classical HLA loci (94).
Several autoimmune diseases have already been investigated
with Immunochip, such as atopic dermatitis (95), ankylosing
spondylitis (96), CD (97), selective IgA Deficiency (98), juvenile
idiopathic arthritis (99), MS (100), RA (101), Sj (102), Ps (103),
SSc (104); the unique vasculitis analyzed with Immunochip has
been Takayasu Arteritis (105). In all these cases, statistically sig-
nificant immunogenetic variants have been demonstrated; at this
time, no Immunochip study has been performed in AAV. Such an
analysis may confirm the results obtained from the two GWAS and
possibly identifying more associated loci with AAV.
TARGETED SEQUENCING
Targeted sequencing is focused on regions statistically associated
by previous studies, such as GWAS. In the case of rare mutations
with high penetrance, the addition of more variants and increased
sample size may be required, involving deep sequencing in a large
number of affected individuals. This approach may add markers
to those already known.
Recently has been demonstrated that targeted sequencing of
pooled samples increases the chance to efficiently and cost-
effectively capture all variation in a more limited target region
selectively amplified in multiple DNA samples (106, 107). Such an
approach allows efficient use of Next Generation Sequencing tech-
nologies, which generate billions of base pairs per experiment, yet
introducing challenges in data processing and analysis to discover
novel variants and assessing their potential association to disease.
In AAV, resequencing will be feasible when several variants will be
discovered from different GWAS or Immunochip analysis.
WHOLE EXOME SEQUENCING
In the human genome, there are about 18,000 genes, which con-
tain exons and introns. Exons are short, functionally important
sequences of DNA which, together, represent only the portion of
the genome that is translated in protein. Whole Exome sequencing
(a targeted exome capture) is a recent strategy designed to sequence
only the coding regions of the genome (which represents 1% of
the human genome or about 30 megabases); this is an effective
method alternative to whole genome sequencing, cheaper and less
complicated in the bioinformatical/statistical analysis.
The whole exome sequencing potentially may identify the
coding variants responsible for both mendelian and common
diseases (108).
Whole exome sequencing study may be applied to AAV cases
for several topics, such as for familial cases, the investigation of
extreme phenotypes, for the finding of mutations or rare variants
of already known or novel susceptibility genes and for pharma-
cogenomic study. Furthermore, the increasing number of suscep-
tibility loci will improve bioinformatic pathway analyses. Investi-
gation of genetically modified animals genetically engineered with
identified susceptibility genes may also provide more knowledge
to the pathophysiology and potentially validate novel treatment
targets.
The elucidation of these novel components may have clini-
cal relevance, as they can be included in genetic-risk modeling
approaches. Moreover, they might represent novel biomarkers for
AAV, enabling physicians to diagnose patients at risk, preferably
before the onset of symptoms, which would greatly reduce the
overall cost to society and the burden on patients.
Most importantly, the causal variants, or other molecules that
have been identified as playing a role in the same pathway, repre-
sent new potential therapeutic targets, not only for AAV but also
other autoimmune diseases.
META-ANALYSIS AND THE -OMICS
Meta-analysis is an important tool to increase the statistical power
and analyze the effect of gene variations across groups of different
ancestries. A huge amount of GWAS data is becoming available,
opening the possibility that future meta-analyses will estimate
effect sizes, determining which genes may predispose to differ-
ent subsets of AAV. Predictive mathematical models integrating
the contributing loci may also be helpful. In addition, it is neces-
sary to understand how specific genetic variants are responsible for
the association and the biological effect. Fine mapping, targeted
sequencing, transcriptomics, proteomics, and metabolomics may
be the future goal for being able to stratify risk patients to truly
develop a personalized approach to care.
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